Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas

Clinical Trial of Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas

The purpose of the study is to evaluate the effects of Transcatheter Arterial Chemoembolization (TACE) with KMG microsphere in treating advance-stage Hepatocellular Carinoma(HCC).

This is a prospective, multicentre, random, controlled clinical trial of Transcatheter Arterial Chemoembolization (TACE)with KMG Microsphere Treating Advance-stage Hepatocellular Carinomas.

Inclusion Criteria:

1. Hepatocellular Carinomas with diagnosis of pathology or cytology or consistent with China 2001 guideline of Clinical Diagnosis Hepatocellular Carinomas
2. clinical stage（The Barcelona Liver Clinic staging system,BCLC B and C)，or can not receive surgical intervention
3. liver function:Child-Pugh A、B
4. PST 0-1（Eastern Cooperative Oncology Group Performance Score ,ECOG）
5. Lifespan≥6 months
6. First time to receive treatment
7. Can accept the follow up
8. informed consent was gotten
9. the number of lesion ≤ 5

Exclusion Criteria:

1. pregnant or lactation woman
2. emotional disturbance
3. serious heart ,lung disfunction or serious diabetes mellitus
4. serious reactiveness infections;（exp:type B or C hepatitis）
5. liver function :Child-Pugh Score C
6. thrombocyte<6×109/L
7. diffuse HCC
8. widespread metastasis
9. serious atherosclerosis
10. acquired immunodeficiency syndrome;AIDS
11. thrombosis or thrombosis event in 6 months
12. renal inadequacy who need hemodialysis or peritoneal dialysis
13. with other tumors except basal cell carcinoma and carcinoma in situ of cervix
14. serious alimentary tract hemorrhage in 4 weeks